Menu
Search Close

News

DNA ImmunoBody® Patent Granted in United States

06th June 2014

Scancell Holdings plc (‘Scancell’ or the ‘Company’), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that a patent for its DNA ImmunoBody® technology has been granted in the United States.

The patent, number 8,742,088, has been granted by The United States Patent and Trademark Office (USPTO) and covers Scancell’s DNA ImmunoBody® platform technology. This patent is key for the protection of the Company’s pipeline of ImmunoBody® vaccines and follows the grant of counterparts in Australia, China and Japan. 

Scancell’s protein ImmunoBody® patent has already been granted in Australia, Canada, Europe, Japan and the United States. 

Dr. Richard Goodfellow, Joint Chief Executive of Scancell, commented:

“We are delighted to have further strengthened our IP portfolio around our proprietary ImmunoBody® platform technology. The United States is a key market for us and this, alongside the recent positive results from the Phase 1/2 trial for our SCIB1 ImmunoBody® in melanoma, demonstrates the strong progress Scancell is making. We look forward to continuing development of our ImmunoBody® platform and advancing our SCIB1 clinical trial, bringing patients one step closer to a new treatment for melanoma.” 

 

 

For Further Information:

Dr Richard Goodfellow, Joint CEO

Professor Lindy Durrant, Joint CEO

Scancell Holdings Plc

Scancell Holdings Plc

+ 44 (0) 20 3727 1000

Camilla Hume/Stephen Keys

Cenkos Securities plc

+ 44 (0) 20 7397 8900

Mo Noonan/Simon Conway

FTI Consulting

+ 44 (0) 20 3727 1000

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1 produced a melanoma-specific immune response and promising survival trend.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

Webcasts, Interviews and Media Coverage

Scancell on verge of recruiting patients with advanced melanoma for UK clinical trials

The immunotherapy specialist gave an update on progress for a “busy and productive” half-year.

Mon, 01 Jul 2019 11:19:00